Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes
PLOS One · 2025
DOI: 10.1371/journal.pone.0332747 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Weixing Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ningbo Haishu People's hospital, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Machine Learning, Neoplasm Recurrence, Local. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Motor proteins play significant roles in cancer progression, but their involvement in biochemical recurrence (BCR) of prostate cancer remains unclear. The objective of the study is to develop a prognostic indicator for BCR using machine learning (ML) and motor protein-related genes (MPRGs).
Methods
The prognosis relevance of the MPRGs in prostate cancer was analyzed by univariate Cox regression. Feature selection and model construction were performed using combinations of multiple machine learning algorithms. Model performance was assessed using receiver operating characteristic curve and C-index. Patients were stratified into high- and low-risk groups based on the risk signature, and comparisons of BCR incidence, gene expression profiles, immune cell infiltration patterns, and drug sensitivity were conducted between these groups. The gene expression of MPRGs were validated in vitro.
Results
Among 120 MPRGs, 17 were differentially expressed, of which 8 were significantly associated with BCR. A novel risk scoring system using a StepCox[forward] + Ridge model based on these 8 MPRGs effectively stratified patients into two different risk groups, and patients with high riskscores had significantly higher BCR rates than those with lower riskscores. Enrichment analysis revealed upregulation of inflammation response, EMT, hypoxia, and estrogen response pathways in the high-risk category, while mitotic spindle, G2M checkpoint, and E2F targets were downregulated. The MPRG-derived risk score correlated positively with M2 macrophage infiltration and ngatively correlated with CD4 T cells and mast cells, and the high-risk category showed higher sensitivity to drugs like cisplatin and bicalutamide. The final nomogram based on MPRGs-derived signature and T stage provided an excellent tool for predicting BCR. In vitro experiments further validated that the expression trends of MPRGs in the risk signature were consistent with the bioinformatics analysis results.
Conclusion
This study developed a novel MPRG-derived risk signature that effectively predicts BCR in prostate cancer, offering valuable insights for clinical management and personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ningbo Haishu People's hospital, Ningbo, Zhejiang, China.
- Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
ORCID-Profile: Weixing Wang
Zitieren
APA
Wang, W., Xie, G., & Wu, Z. (2025). Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes. PLOS One. https://doi.org/10.1371/journal.pone.0332747
Vancouver
Wang W, Xie G, Wu Z. Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes. PLOS One. 2025. doi:10.1371/journal.pone.0332747
BibTeX
@article{Wang2025,
author = {Wang, Weixing and Xie, Guohai and Wu, Zhonggao},
title = {Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332747}
}
EUVIMED